Karen Akinsanya - 02 Mar 2026 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Issuer symbol
SDGR
Transactions as of
02 Mar 2026
Net transactions value
-$26,454
Form type
4
Filing time
03 Mar 2026, 16:31:41 UTC
Previous filing
25 Jun 2025
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Akinsanya Karen President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya 03 Mar 2026 0001797672

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SDGR Common Stock Award $0 +24,250 +155% $0.000000 39,875 02 Mar 2026 Direct F1
transaction SDGR Common Stock Award $0 +6,077 +15% $0.000000 45,952 02 Mar 2026 Direct F2
transaction SDGR Common Stock Award $0 +27,576 +60% $0.000000 73,528 02 Mar 2026 Direct F3
transaction SDGR Common Stock Sale $26,454 -2,206 -3% $11.99 71,322 02 Mar 2026 Direct F4, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Award $0 +48,500 $0.000000 48,500 02 Mar 2026 Common Stock 48,500 $12.15 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 2, 2026 and will vest in equal installments on each of March 9, 2027, 2028, 2029 and 2030, subject to the reporting person's continued service with the company.
F2 Represents the portion of the performance-based restricted stock units ("PRSUs") that were previously granted to the reporting person on February 9, 2023 in connection with the Issuer's annual grant of equity in 2023, that vested on March 2, 2026 following certification by the compensation committee of the Issuer's board of directors of the level of achievement of certain performance metrics for the PRSUs.
F3 Represents PRSUs previously granted to the reporting person on March 4, 2024, for which the compensation committee of the Issuer's board of directors certified on March 2, 2026 the level of achievement of the performance metrics for the PRSUs. The PRSUs will vest upon the filing of the Issuer's Annual Report on Form 10-K for the year ended December 31, 2026, subject to the reporting person's continued service with the company.
F4 This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PRSUs. The sale does not represent a discretionary trade by the reporting person.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) of this Form 4.
F6 Includes an aggregate of 67,451 unvested RSUs.
F7 The option was granted on March 2, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 2, 2027 and the remainder are scheduled to vest in equal monthly installments through March 2, 2030, subject to the reporting person's continued service with the company.

Remarks:

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships